-
Je něco špatně v tomto záznamu ?
Molecular design, synthesis and anticancer activity of new thiopyrano[2,3-d]thiazoles based on 5-hydroxy-1,4-naphthoquinone (juglone)
I. Ivasechko, A. Lozynskyi, J. Senkiv, P. Roszczenko, Y. Kozak, N. Finiuk, O. Klyuchivska, N. Kashchak, N. Manko, Z. Maslyak, D. Lesyk, A. Karkhut, S. Polovkovych, R. Czarnomysy, O. Szewczyk, A. Kozytskiy, O. Karpenko, D. Khyluk, A. Gzella, K....
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- doxorubicin farmakologie MeSH
- lidé MeSH
- molekulární struktura MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- naftochinony * farmakologie MeSH
- proliferace buněk MeSH
- protinádorové látky * chemie MeSH
- screeningové testy protinádorových léčiv MeSH
- simulace molekulového dockingu MeSH
- thiazoly chemie MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
A series of 11-substituted 9-hydroxy-3,5,10,11-tetrahydro-2H-benzo[6,7]thiochromeno[2,3-d][1,3]thiazole-2,5,10-triones 3.1-3.13 were synthesized via hetero-Diels-Alder reaction of 5-ene-4-thioxo-2-thiazolidinones and 5-hydroxy-1,4-naphthoquinone (juglone). The structure of newly synthesized compounds was established by means of spectral data and a single-crystal X-ray diffraction analysis. The synthesized compounds were tested on a panel of cell lines representing different types of cancer as well as normal and pseudonormal cells and peripheral human blood lymphocytes. Compound 3.10 was found to be the most active derivative, exhibiting a cytotoxic effect similar to doxorubicin's one (IC50 ranged from 0.6 to 5.98 μM), but less toxic to normal and pseudonormal cells. All synthesized compounds were able to interact with DNA, although their anticancer activity did not correlate with the potency of interaction with DNA. The status of p53 in colorectal cancer cells correlated with the activity of the synthesized derivatives 3.1, 3.7, and 3.10. Compound 3.10 did not have an acute toxic effect on the body of С57BL/6 mice, unlike the well-known anticancer drug doxorubicin, which was used as a positive control. The injection of 3.10 (20 mg/kg) to mice had no effect on the counts of leukocytes, erythrocytes, platelets and hemoglobin level in their blood, in contrast to doxorubicin, which caused anemia and leukopenia, indicating bio-tolerance of 3.10in vivo.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010486
- 003
- CZ-PrNML
- 005
- 20230801132445.0
- 007
- ta
- 008
- 230718s2023 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2023.115304 $2 doi
- 035 __
- $a (PubMed)37001390
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Ivasechko, Iryna $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
- 245 10
- $a Molecular design, synthesis and anticancer activity of new thiopyrano[2,3-d]thiazoles based on 5-hydroxy-1,4-naphthoquinone (juglone) / $c I. Ivasechko, A. Lozynskyi, J. Senkiv, P. Roszczenko, Y. Kozak, N. Finiuk, O. Klyuchivska, N. Kashchak, N. Manko, Z. Maslyak, D. Lesyk, A. Karkhut, S. Polovkovych, R. Czarnomysy, O. Szewczyk, A. Kozytskiy, O. Karpenko, D. Khyluk, A. Gzella, K. Bielawski, A. Bielawska, P. Dzubak, S. Gurska, M. Hajduch, R. Stoika, R. Lesyk
- 520 9_
- $a A series of 11-substituted 9-hydroxy-3,5,10,11-tetrahydro-2H-benzo[6,7]thiochromeno[2,3-d][1,3]thiazole-2,5,10-triones 3.1-3.13 were synthesized via hetero-Diels-Alder reaction of 5-ene-4-thioxo-2-thiazolidinones and 5-hydroxy-1,4-naphthoquinone (juglone). The structure of newly synthesized compounds was established by means of spectral data and a single-crystal X-ray diffraction analysis. The synthesized compounds were tested on a panel of cell lines representing different types of cancer as well as normal and pseudonormal cells and peripheral human blood lymphocytes. Compound 3.10 was found to be the most active derivative, exhibiting a cytotoxic effect similar to doxorubicin's one (IC50 ranged from 0.6 to 5.98 μM), but less toxic to normal and pseudonormal cells. All synthesized compounds were able to interact with DNA, although their anticancer activity did not correlate with the potency of interaction with DNA. The status of p53 in colorectal cancer cells correlated with the activity of the synthesized derivatives 3.1, 3.7, and 3.10. Compound 3.10 did not have an acute toxic effect on the body of С57BL/6 mice, unlike the well-known anticancer drug doxorubicin, which was used as a positive control. The injection of 3.10 (20 mg/kg) to mice had no effect on the counts of leukocytes, erythrocytes, platelets and hemoglobin level in their blood, in contrast to doxorubicin, which caused anemia and leukopenia, indicating bio-tolerance of 3.10in vivo.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a thiazoly $x chemie $7 D013844
- 650 12
- $a protinádorové látky $x chemie $7 D000970
- 650 12
- $a naftochinony $x farmakologie $7 D009285
- 650 _2
- $a doxorubicin $x farmakologie $7 D004317
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lozynskyi, Andrii $u Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine
- 700 1_
- $a Senkiv, Julia $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
- 700 1_
- $a Roszczenko, Piotr $u Department of Biotechnology, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
- 700 1_
- $a Kozak, Yuliia $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
- 700 1_
- $a Finiuk, Nataliya $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
- 700 1_
- $a Klyuchivska, Olga $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
- 700 1_
- $a Kashchak, Nataliya $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
- 700 1_
- $a Manko, Nazar $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
- 700 1_
- $a Maslyak, Zvenyslava $u Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine, General Chuprynky 45, Lviv, 79044, Ukraine
- 700 1_
- $a Lesyk, Danylo $u Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine
- 700 1_
- $a Karkhut, Andriy $u Department of Technology of Biologically Active Substances, Pharmacy and Biotechnology, Lviv Polytechnic National University, Bandera 12, Lviv, 79013, Ukraine
- 700 1_
- $a Polovkovych, Svyatoslav $u Department of Technology of Biologically Active Substances, Pharmacy and Biotechnology, Lviv Polytechnic National University, Bandera 12, Lviv, 79013, Ukraine
- 700 1_
- $a Czarnomysy, Robert $u Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
- 700 1_
- $a Szewczyk, Olga $u Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
- 700 1_
- $a Kozytskiy, Andriy $u Enamine Ltd, Chervonotkatska Street 78, Kyiv, 02094, Ukraine; L.V. Pysarzhevsky Institute of Physical Chemistry, National Academy of Sciences of Ukraine, Nauky Avenue 31, Kyiv, 03028, Ukraine
- 700 1_
- $a Karpenko, Olexandr $u Enamine Ltd, Chervonotkatska Street 78, Kyiv, 02094, Ukraine
- 700 1_
- $a Khyluk, Dmytro $u Department of Organic Chemistry, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 4A Chodzki, Lublin, 20-093, Poland
- 700 1_
- $a Gzella, Andrzej $u Department of Organic Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780, Poznan, Poland
- 700 1_
- $a Bielawski, Krzysztof $u Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
- 700 1_
- $a Bielawska, Anna $u Department of Biotechnology, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
- 700 1_
- $a Dzubak, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 77900, Olomouc, Czech Republic
- 700 1_
- $a Gurska, Sona $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 77900, Olomouc, Czech Republic
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 77900, Olomouc, Czech Republic
- 700 1_
- $a Stoika, Rostyslav $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine. Electronic address: stoika.rostyslav@gmail.com
- 700 1_
- $a Lesyk, Roman $u Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine; Department of Biotechnology and Cell Biology, Medical College, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland. Electronic address: dr_r_lesyk@org.lviv.net
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 252, č. - (2023), s. 115304
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37001390 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132442 $b ABA008
- 999 __
- $a ok $b bmc $g 1963108 $s 1196751
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 252 $c - $d 115304 $e 20230324 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20230718